Scarica l'app Stockscreener
410.82
1.46%
5.92
Precedente Chiudi:
$404.90
Aprire:
$402.795
Volume 24 ore:
1.71M
Relative Volume:
1.29
Capitalizzazione di mercato:
$59.22B
Reddito:
$2.50B
Utile/perdita netta:
$-226.32M
Rapporto P/E:
-250.32
EPS:
-1.6412
Flusso di cassa netto:
$71.51M
1 W Prestazione:
-0.62%
1M Prestazione:
-0.23%
6M Prestazione:
+105.24%
1 anno Prestazione:
+116.71%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$383.76
$416.00
Portata 52W:
$181.00
$437.41
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
410.82 | 59.22B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
693.02 | 256.24B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.00 | 163.09B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
177.49 | 50.04B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
468.55 | 46.03B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-23 | Iniziato | Roth Capital | Buy |
| 2026-09-09 | Ripresa | UBS | Buy |
| 2026-09-08 | Iniziato | Rothschild & Co Redburn | Buy |
| 2026-06-26 | Ripresa | Bernstein | Outperform |
| 2026-06-12 | Ripresa | RBC Capital Mkts | Outperform |
| 2026-06-02 | Ripresa | Wolfe Research | Outperform |
| 2026-04-14 | Iniziato | William Blair | Outperform |
| 2026-01-07 | Iniziato | Citigroup | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-27 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Ripresa | Wells Fargo | Equal Weight |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Zacks Investment Research
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree. - The Motley Fool
Natera Co-Founder Sheena Jonathan Disposes of 3,150 Shares Under Rule 10b5-1 Plan on October 21, 2026 - Kalkine Media
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Natera Director Sheena Jonathan Files to Sell 9,450 Shares Valued at $3.88 Million - Kalkine Media
After a $7.01M September sale, a Natera (NTRA) director proposes another share sale. - Stock Titan
Natera Partners With TransCode to Advance Colorectal Cancer Trial - Zacks Investment Research
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Australia
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Nigeria
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com India
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? - Zacks Investment Research
Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Nigeria
Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Canada
Under a preset plan, Natera (NTRA)'s chairman sells 50,000 shares; he also exercises options. - Stock Titan
Natera Director Matthew Rabinowitz Files Form 144 to Sell 50,000 Shares Valued at $19.7M - Kalkine Media
$19.7M in Natera (NTRA) shares is proposed for sale following three September sales. - Stock Titan
Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Matthew Rabinowitz Donates 6,000 Natera Shares to Charity on October 7, 2026 - Kalkine Media
Natera CEO Steven Chapman sells $526k in common stock By Investing.com - Investing.com UK
Natera CEO Steven Chapman sells $526k in common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under a trading plan. - Stock Titan
Morgan Stanley Smith Barney is broker for a proposed 1,273-share sale at Natera (NTRA). - Stock Titan
After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com UK
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Nigeria
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan
Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Zacks Investment Research
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera (NASDAQ: NTRA) co-founder sells 9,150 shares under 10b5-1 plan - Stock Titan
Natera (NASDAQ: NTRA) chair unloads stock in preset plan - Stock Titan
Trust tied to Natera (NASDAQ: NTRA) eyes new stock sale after multimillion-dollar trades - Stock Titan
Understanding Momentum Shifts in (NTRA) - Stock Traders Daily
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - webull.com
Natera(NTRA.US) Officer Sells US$16.4 Million in Common Stock - Moomoo
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com South Africa
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - Investing.com
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com India
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - investing.com
Executive chair of Natera (NTRA) sells 50,000 shares - Stock Titan
Insider at Natera (NTRA) plans stock sale, with size detailed in new SEC notice - Stock Titan
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - simplywall.st
NTRA Maintains Buy Rating by UBS -- Price Target Raised to $435 - GuruFocus
3 Reasons Investors Love Natera (NTRA) - Yahoo Finance
UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating - Moomoo
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Natera Inc Azioni (NTRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MICHAEL BROPHY | OFFICER |
Oct 27 '26 |
Proposed Sale |
404.90 |
771 |
312,178 |
0 |
| SOLOMON MOSHKEVICH | OFFICER |
Oct 27 '26 |
Proposed Sale |
404.90 |
997 |
403,685 |
0 |
| JOHN FESKO | OFFICER |
Oct 27 '26 |
Proposed Sale |
404.90 |
771 |
312,178 |
0 |
| STEVEN CHAPMAN | OFFICER |
Oct 27 '26 |
Proposed Sale |
404.90 |
2,236 |
905,356 |
0 |
| MATTHEW RABINOWITZ | DIRECTOR |
Oct 27 '26 |
Proposed Sale |
404.90 |
1,697 |
687,115 |
0 |
| DANIEL RABINOWITZ | OFFICER |
Oct 27 '26 |
Proposed Sale |
404.90 |
873 |
353,478 |
0 |
| Sheena Jonathan | Director |
Oct 21 '26 |
Proposed Sale |
410.55 |
9,450 |
3,879,737 |
0 |
| Sheena Jonathan | CO-FOUNDER |
Oct 21 '26 |
Sale |
410.55 |
3,150 |
1,293,246 |
218,164 |
| Sheena Jonathan | CO-FOUNDER |
Oct 16 '26 |
Sale |
402.47 |
1,500 |
603,710 |
8,250 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Oct 15 '26 |
Option Exercise |
10.41 |
50,000 |
520,500 |
2,169,394 |
0.87%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):